Nemorubicin. Antineoplastic anthracycline

Drugs of the Future

Volumn 22, Issue 12, 1997, Pages 1319-1324

  Graul, A ^a   Leeson, P A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DEXAMETHASONE; DOXORUBICIN; GLYCOPROTEIN P; NEMORUBICIN; UNCLASSIFIED DRUG;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CELL LINE; CROSS RESISTANCE; CYTOTOXICITY; DNA STRAND BREAKAGE; DRUG ACTIVATION; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG UPTAKE; FATIGUE; HUMAN; IN VITRO STUDY; LIPOPHILICITY; LIVER DYSFUNCTION; LIVER MICROSOME; NAUSEA; NEPHROTOXICITY; NONHUMAN; SOLID TUMOR; TUMOR CELL; VOMITING;

EID: 0031405205     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.12.433151     Document Type: Article

References (44)

1. Bargiotti, A., Zini, P., Penco, S., Giuliani, F. (Farmitalia Carlo Erba SpA). Novel morpholino derivs. of daunorubicins and doxorubicins. BE 0904431, DE 3609052, GB 2172594, JP 86221194, US 4672057.
2. Graul, A., Prous, J., Castañer, J. Annamycin. Drugs Fut 1997, 22: 948-55.
3. Lau, D.H.M., Lewis, A.D., Durán, G.E., Sikic, B.I. The cellular and biochemical pharmacology of the methoxy morpholino derivative of doxorubicin, FCE 23762. Proc Amer Assoc Cancer Res 1991, 32: Abst 1970.
4. Duran, G.E., Lau, D.H.M., Lewis, A.D., Kühl, J.-S., Bämmler, T.K., Sikic, B.I. Differential single-versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues. Cancer Chemother Pharmacol 1996, 38: 210-6.
5. Ballinari, D., Pennella, G., Suarato, A., Spreafico, F., Grandi, M. In vitro intracellular accumulation of FCE 23762, a new anthracycline active on DX-resistant tumor cells. Eur J Cancer 1991, 27(Suppl. 3): Abst 5.003.
6. Ripamonti, M., Farao, M., Pastori, A., Pesenti, E., Suarato, A., Spreafico, F., Grandi, M. Spectrum of antitumor activity of FCE 23762, a novel anthracycline active on DX-resistant leukemias. Eur J Cancer 1991, 27(Suppl. 3): Abst 5.023.
7. Kühl, J.-S., Durán, G.E., Chao, N.J., Sikic, B.I. Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. Cancer Chemother Pharmacol 1993, 33: 10-6.
8. Alvino, E., Gilberti, S., Cantagallo, D., Massoud, R., Gatteschi, A., Tentori, L., Bonmassar, E., D'Atri, S. In vitro antitumor activity of 3′-desamino-3′(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds. Cancer Chemother Pharmacol 1997, 40: 180-4.
9. Ripamonti, M., Pezzoni, G., Pesenti, E., Pastori, A., Farao, M., Bargiotti, A., Suarato, A., Spreafico, F., Grandi, M. In vivo antitumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells. Brit J Cancer 1992, 65: 703-7.
10. Grandi, M., Pezzoni, G., Ballinari, D., Capolongo, L., Suarato, A., Bargiotti, A., Faiardi, D., Spreafico, F. Novel anthracycline analogs. Cancer Treat Rev 1990, 17: 133-8.
11. Pezzoni, G., Grandi, M., Ballinari, D., Bargiotti, A., Suarato, A., Giuliani, F.C., Spreafico, F. Antitumor activity of FCE 23762, an anthracycline derivative active against DX-resistant cells. Proc Amer Assoc Cancer Res 1989, 30: Abst 2112.
12. Geroni, C., Ripamonti, M., Marsiglio, A., Pennella, G., Gornati, C., Grandi, M. Pretreatment with dexamethasone does not interfere with the antitumor activity of FCE 23762 on mice bearing P388/DX leukemia. Proc Amer Assoc Cancer Res 1995, 36: Abst 2133.
13. Geroni, M.C., Pennella, G., Ripamonti, M., Bargiotti, A., Suarato, A., Grandi, M. The (2′R) and (2′S) enantiomers of methoxymorpholinyldoxorubicin present equivalent antitumor activity and select two different modes of resistance. Proc Amer Assoc Cancer Res 1994, 35: Abst 2415.
14. Geroni, C., Pesenti, E., Broggini, M., Belvedere, G., Tagliabue, G., D'Incalci, M., Pennella, G., Grandi, M. L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives. Brit J Cancer 1994, 69: 315-9.
15. Geroni, M.C., Pesenti, E., Broggini, M., Amboldi, N., D'Incalci, M., Grandi, M. Cells resistant to methoxymorpholinyl-doxorubicin (FCE 23762) are specifically resistant only to the class of morpholinyl and methoxymorpholinyl anthracyclines: In vitro and in vivo characterization. Proc Amer Assoc Cancer Res 1992, 33: Abst 2775.
16. Praet, M., Stryckmans, P., Ruysschaert, J.-M. Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells. Biochem Pharmacol 1996, 51: 1341-8.
17. Michieli, M., Damiani, D., Michelutti, A., Melli, C., Ermacora, A., Geromin, A., Fanin, R., Russo, D., Baccarani, M. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin. Haematologica 1996, 81: 295-301.
18. Angiuli, P., Fiorentini, F., Breda, M., Battaglia, R., Basileo, G., Castelli, M.G., Poggesi, I., Salgarollo, G., Rocchetti, M. Pharmacokinetics of methoxymorpholino doxorubicin (FCE 23762) in female rats. Ann Oncol 1996, 7(Suppl. 5): Abst 631P.
19. Breda, M., Pianezzola, E., Strolin Benedetti, M. Stretching HPLC sensitivity to measure subnanogram levels of FCE 23762, a novel anthracycline, and its 13-dihydro metabolite in human plasma. Methodol Surv Bioanal Drugs 1994, 23: 263-8.
20. Geroni, C., Caruso, M., Marsiglio, A., Lovisolo, P.P., Pennella, G., Marchini, S., Grandi, M. Methoxymorpholinyldx (FCE23762, PNU152243) metabolism: Isolation, structure identification, and biological characterization of active metabolites. Proc Amer Assoc Cancer Res 1997, 38: Abst 1572.
21. Breda, M., Pianezzola, E., Strolin Benedetti, M. Determination of 3′-deamino-3′-[2(S)-methoxy-4-morpholinyl]doxorubicin, a new morphological anthracycline, in plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr Biomed Appl 1992, 578: 309-15.
22. Farina, A., Quaglia, M.G., Doldo, A., Calandra, S., Gallo, F.R. Analysis of FCE 23762 (methoxymorpholinodoxorubicin hydrochloride), a new antitumour agent, by HPTLC and scanning densitometry. J Pharm Biomed Anal 1993, 11: 1215-8.
23. Rossini, M.L., Farina, M. Stability studies with a high-performance liquid chromatographic method for the determination of a new anthracycline analogue, 3′-deamino-3′-[2-(S)-methoxy-4-morpholino]doxorubicin (FCE 23762), in the final drug formulation. J Chromatogr 1992, 593: 47-53.
24. Danesi, R., Agen, C., Grandi, M., Nardini, V., Bevilacqua, G., Del Tacca, M. 3′-Deamino-3′-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): A new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity. Eur J Cancer 1993, 29A: 1560-5.
25. Fornasiero, M.C., Ferrari, M., Gnocchi, P., Trizio, D., Isetta, A.M. Immunodepressive activity of FCE 23762 on humoral and cell-mediated immune responses in normal mice: Comparison with doxorubicin. Agents Actions 1992, 37: 311-8.
26. Vasey, P.A., Bissett, D., Strolin-Benedetti, M., Poggesi, I., Breda, M., Adams, L., Wilson, P., Pacciarini, M.A., Kaye, S.B., Cassidy, J. Phase I clinical and pharmacokinetic study of 3′-deamino-3′-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762). Cancer Res 1995, 55: 2090-6.
27. Skoog, L.A., Ratain, M.J., O'Brien, S.M., Schilsky, R.L., Vogelzang, N.J., Gerber, M., Narang, P.K., Nicol, S.J. Phase I trial of methoxymorpholinodoxorubicin (FCE23762, MMD): On a daily x3 schedule. Proc Amer Soc Clin Oncol 1995, 14: Abst 1582.
28. Skoog, L.A., Ratain, M.J., O'Brien, S.M., Cooper, N., Schilsky, R.L., Vogelzang, N.J., Gerber, M., Narang, P.K., Nicol, S.J. Phase I trial of methoxymorpholinodoxorubicin (FCE23762, MMD): On a daily x3 schedule. Proc Amer Soc Clin Oncol 1996, 15: Abst 1531.
29. Ratain, M.J., Skoog, L.A., O'Brien, S.M., Cooper, N., Schilsky, R.L., Vogelzang, N.J., Gerber, M., Narang, P.K., Nicol, S.J. Phase I study of 3′-deamino-3′-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule. Ann Oncol 1997, 8: 807-9.
30. Groen, H.J.M., Droz, J.P., Hanauske, A.R., Verwey, J., van Oosterom, A.T., DiPalma, M., Marty, M., Sorio, R., Pacciarini, M.A., Lassus, M., de Vries, E.G.E. A feasibility study with FCE 23762 every 4 weeks in adults with solid tumors. Proc Amer Soc Clin Oncol 1995, 14: Abst 1515.
31. Bakker, M., Groen, H.J.M., Oges, D.R.A., Droz, J.P., Hanauske, A.R., Verwey, J., van Oosterom, A.T., Pacciarini, M.A., Lassus, M., de Vries, E.G.E. A feasibility study with FCE 23762 every 4 weeks in solid tumor patients. Pharm World Sci 1995, 17(6, Suppl. O): O8.
32. Bakker, M., Droz, J.P., Hanauske, A.R., Verwey, J., van Oosterom, A.T., Pacciarini, M.A., Domenigoni, L., Uges, D.R.A., Groen, H.J.M., de Vries, E.G.E. Update report on a feasibility and pharmacokinetic study of FCE 23762 every 4 weeks in solid tumor patients. 9th NCI-EORTC Symp New Drugs Cancer Ther (March 12-15, Amsterdam) 1996, Abst 337.
33. Taub, R.N., Paciucci, A.P., Behrens, B., Isaacs, R., Baker, L., Christman, K., Budd, G.T., Nicol, S., Akhipov, A. Phase II study of methoxymorpholinodoxorubicin in advanced sarcomas [PNU/ S2243 (FCE23762)]. Proc Amer Soc Clin Oncol 1997, 16: Abst 1831.
34. Vasey, P.A., Bissett, D., Cassidy, J., Kaye, S.B. Methoxymorpholinyl-doxorubicin (FCE 23762) - Clinical phase I study in adults with refractory solid tumours. Ann Oncol 1994, 5(Suppl. 5): Abst 268.
35. Ripamonti, M., Capolongo, L., Melegaro, G., Gornati, C., Bargiotti, A., Caruso, M., Grandi, M., Suarato, A. Morpholinylanthracyclines: Cytotoxicity and antitumor activity of differently modified derivatives. Invest New Drugs 1996, 14: 139-46.
36. Taub, R.N., Krishna, S., Roy, D.K. Cytotoxicity and intracellular distribution of 3′-deamino-3′-(2-methoxy-4-morpholinyl)-doxorubicin (MDOX) in sensitive- and multidrug-resistant cell lines. Proc Amer Assoc Cancer Res 1994, 35: Abst 2564.
37. Suarato, A., Angelucci, F., Bargiotti, A., Caruso, M., Grandi, M., Ripamonti, M. Synthesis and study of the structure activity relationships of new classes of anthracyclines. 205th ACS Natl Meet (March 28-April 2, Denver) 1993, Abst CARB 20.
38. Geroni, M.C., Pennella, G., Villa, A.M., Doglia, S.M., Trizio, D., Grandi, M. Resistance to methoxymorpholinyldoxorubicin (MMRDX-FCE 23762) studied by laser scanning confocal fluorescence microscopy (LSCFM). Proc Amer Assoc Cancer Res 1994, 35: Abst 58.
39. van der Graaf, W.T.A., Mulder, N.H., Meijer, C., de Vries, E.G.E. The role of methoxymorpholino anthracycline and cyanomorpholino anthracycine in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts. Cancer Chemother Pharmacol 1995, 35: 345-8.
40. Plumb, J.A., Workman, P., Kaye, S.B. Circumvention of the multidrug resistance phenotype by methoxymorpholino doxorubicin. 7th NCI-EORTC Symp New Drugs Cancer Ther (March 17-20, Amsterdam) 1992, Abst 066.
41. Marsiglio, A., Ripamonti, M., Amboldi, N., Suarato, A., Ballinari, D., Grandi, M. Intratumor accumulation of MMRDX and DX on s.c. implanted P388 and P388/DX leukemia cells. Ann Oncol 1994, 5(Suppl. 5): Abst 391.
42. Lau, D.H.M., Duran, G.E., Lewis, A.D., Sikic, B.I. Metabolic conversion of methoxymorpholinyl doxorubicin: From a DNA strand breaker to a DNA cross-linker. Brit J Cancer 1994, 70: 79-84.
43. Vasey, P.A., Bisset, D., Kaye, S.B., Cassidy, J. Clinical phase I study of methoxymorphilinyl-doxorubicin (FCE23762). Proc Amer Assoc Cancer Res 1994, 35: Abst 2379.
44. Quaglia, M.G., Farina, A., Kilár, F., Fanali, S., Bossù, E., Dell' Aquila, C. Analysis of a new doxorubicin derivative (FCE 23762) and related compounds by high performance capillary electrophoresis. J Liq Chromatogr 1994, 17: 3911-23.